Literature DB >> 31482378

Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.

Finn Holler1, Daniel A Heinrich1, Christian Adolf1, Benjamin Lechner1, Martin Bidlingmaier1, Graeme Eisenhofer2, Tracy Ann Williams1,3, Martin Reincke4.   

Abstract

PURPOSE OF REVIEW: Steroid profiling and immunohistochemistry are both promising new tools used to improve diagnostic accuracy in the work-up of primary aldosteronism (PA) and to predict treatment outcomes. Herein, we review the recent literature and present an outlook to the future of diagnostics and therapeutic decision-making in patients with PA. RECENT FINDING: PA is the most common endocrine cause of arterial hypertension and unilateral forms of the disease are potentially curable by surgical resection of the overactive adrenal. Recent studies have shown that adrenal steroid profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) can be helpful for subtyping unilateral and bilateral forms of PA, classifying patients with a unilateral aldosterone-producing adenoma (APA) according to the presence of driver mutations of aldosterone production in APAs, and potentially predicting the outcomes of surgical treatment for unilateral PA. Following adrenalectomy, immunohistochemistry of aldosterone synthase (CYP11B2) in resected adrenals is a new tool to analyze "functional" histopathology and may be an indicator of biochemical outcomes after surgery. Biochemical and clinical outcomes of therapy in PA vary widely among patients. Peripheral venous steroid profiling at baseline could improve diagnostic accuracy and help in surgical decision-making in cases of a suspected APA; results of "functional" histopathology could help determine which patients are likely to need close post-surgical follow-up for persistent aldosteronism.

Entities:  

Keywords:  Adrenalectomy; Immunohistochemistry; LC-MS; Outcome; Primary aldosteronism; Steroid profiling

Mesh:

Substances:

Year:  2019        PMID: 31482378     DOI: 10.1007/s11906-019-0985-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  80 in total

1.  PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate.

Authors:  M D Gross; B Shapiro; R T Kloos; B Dwamena
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

2.  Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites.

Authors:  Caroline Schirpenbach; Lysann Seiler; Christiane Maser-Gluth; Frank Rüdiger; Christian Nickel; Felix Beuschlein; Martin Reincke
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

3.  The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma.

Authors:  Rasa Zarnegar; William F Young; James Lee; Matthew P Sweet; Electron Kebebew; David R Farley; Geoffrey B Thompson; Clive S Grant; Orlo H Clark; Quan-Yang Duh
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

4.  A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Chiara Caliumi; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Chiara Ganzaroli; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Mee-Jung Mattarello; Angelica Moretti; Gaetana Palumbo; Gabriele Parenti; Enzo Porteri; Andrea Semplicini; Damiano Rizzoni; Ermanno Rossi; Marco Boscaro; Achille Cesare Pessina; Franco Mantero
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

5.  High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.

Authors:  Michael Stowasser; Richard D Gordon; Thanuja G Gunasekera; Diane C Cowley; Gregory Ward; Colin Archibald; B Mark Smithers
Journal:  J Hypertens       Date:  2003-11       Impact factor: 4.844

6.  Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.

Authors:  Georg Zettinig; Markus Mitterhauser; Wolfgang Wadsak; Alexander Becherer; Christian Pirich; Heinrich Vierhapper; Bruno Niederle; Robert Dudczak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

7.  A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.

Authors:  David S Geller; Junhui Zhang; Max V Wisgerhof; Cedric Shackleton; Michael Kashgarian; Richard P Lifton
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

8.  Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature.

Authors:  Franco Lumachi; Mario Ermani; Stefano M M Basso; Decio Armanini; Maurizio Iacobone; Gennaro Favia
Journal:  Am Surg       Date:  2005-10       Impact factor: 0.688

9.  [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes.

Authors:  Stefanie Hahner; Andrea Stuermer; Michael Kreissl; Christoph Reiners; Martin Fassnacht; Heribert Haenscheid; Felix Beuschlein; Martina Zink; Katharina Lang; Bruno Allolio; Andreas Schirbel
Journal:  J Clin Endocrinol Metab       Date:  2008-04-08       Impact factor: 5.958

Review 10.  Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism.

Authors:  Marlies J E Kempers; Jacques W M Lenders; Lieke van Outheusden; Gert Jan van der Wilt; Leo J Schultze Kool; Ad R M M Hermus; Jaap Deinum
Journal:  Ann Intern Med       Date:  2009-09-01       Impact factor: 25.391

View more
  9 in total

1.  Reliability Analysis of a Functional Diagnostic Test for Primary Hyperaldosteronism Based on Data Analysis.

Authors:  Yan Wang; Jun Cai
Journal:  Comput Intell Neurosci       Date:  2022-06-27

Review 2.  Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review.

Authors:  Marta Araujo-Castro; Pablo Valderrábano; Héctor F Escobar-Morreale; Felicia A Hanzu; Gregori Casals
Journal:  Endocrine       Date:  2020-11-21       Impact factor: 3.633

Review 3.  The Potential Role of Aldosterone-Producing Cell Clusters in Adrenal Disease.

Authors:  Jung Soo Lim; William E Rainey
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.936

Review 4.  Primary aldosteronism diagnostics: KCNJ5 mutations and hybrid steroid synthesis in aldosterone-producing adenomas.

Authors:  Juilee Rege; Adina F Turcu; William E Rainey
Journal:  Gland Surg       Date:  2020-02

Review 5.  Primary aldosteronism.

Authors:  Sean M Wrenn; Anand Vaidya; Carrie C Lubitz
Journal:  Gland Surg       Date:  2020-02

6.  Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings.

Authors:  Huiping Wang; Fen Wang; Yushi Zhang; Jin Wen; Dexin Dong; Xiaoyan Chang; Hao Sun; Xiaosen Ma; Yunying Cui; Shi Chen; Lin Lu; Weidong Ren; Anli Tong; Yuxiu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

Review 7.  Clinical Translationality of KCNJ5 Mutation in Aldosterone Producing Adenoma.

Authors:  Takumi Kitamoto; Tetsuo Nishikawa
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

8.  Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS.

Authors:  Carmina Teresa Fuss; Katharina Brohm; Max Kurlbaum; Anke Hannemann; Sabine Kendl; Martin Fassnacht; Timo Deutschbein; Stefanie Hahner; Matthias Kroiss
Journal:  Eur J Endocrinol       Date:  2021-01       Impact factor: 6.664

9.  Long-chain noncoding RNA-GAS5/hsa-miR-138-5p attenuates high glucose-induced cardiomyocyte damage by targeting CYP11B2.

Authors:  Xiaozhen Zhuo; Kai Bai; Yingxian Wang; Peining Liu; Wen Xi; Jianqing She; Junhui Liu
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.